Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Stéphanie, Braillard"'
Autor:
Katrien Van Bocxlaer, Diana Caridha, Chad Black, Brian Vesely, Susan Leed, Richard J. Sciotti, Gert-Jan Wijnant, Vanessa Yardley, Stéphanie Braillard, Charles E. Mowbray, Jean-Robert Ioset, Simon L. Croft
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 11, Iss , Pp 129-138 (2019)
Objectives: Drugs for Neglected Diseases initiative (DNDi) has identified three chemical lead series, the nitroimidazoles, benzoxaboroles and aminopyrazoles, as innovative treatments for visceral leishmaniasis. The leads discovered using phenotypic s
Externí odkaz:
https://doaj.org/article/85d89c5c5d1b46e5bb81f2a521136ced
Autor:
Magali Van den Kerkhof, Philippe Leprohon, Dorien Mabille, Sarah Hendrickx, Lindsay B. Tulloch, Richard J. Wall, Susan Wyllie, Eric Chatelain, Charles E. Mowbray, Stéphanie Braillard, Marc Ouellette, Louis Maes, Guy Caljon
Publikováno v:
Microorganisms, Vol 9, Iss 7, p 1408 (2021)
Current treatment options for visceral leishmaniasis have several drawbacks, and clinicians are confronted with an increasing number of treatment failures. To overcome this, the Drugs for Neglected Diseases initiative (DNDi) has invested in the devel
Externí odkaz:
https://doaj.org/article/3fffc5e0d8f34c3a82d0f26fc93ce6de
Autor:
Katrien Van Bocxlaer, Kerri-Nicola McArthur, Andy Harris, Mo Alavijeh, Stéphanie Braillard, Charles E. Mowbray, Simon L. Croft
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 516 (2021)
In cutaneous leishmaniasis (CL), parasites reside in the dermis, creating an opportunity for local drug administration potentially reducing adverse effects and improving treatment adherence compared to current therapies. Polymeric film-forming system
Externí odkaz:
https://doaj.org/article/09f23d2ed7bf4d9886ffd4f7f491d4d7
Autor:
Stéphanie Braillard, Jason Speake, Sandra Carvalho, Yvonne Freund, Gavin A. Whitlock, Guy Caljon, Bakela Nare, Paul Alan Glossop, Victoriano Corpas-López, Fabio Zuccotto, Louis Maes, Davide Bello, Ian H. Gilbert, Susan Wyllie, Bharathi Pandi, Iva Lukac, Robert T. Jacobs, Magali Van den Kerkhof, Vanessa Yardley, Charles E. Mowbray, Richard J. Wall, Stephen Patterson
Publikováno v:
Journal of Medicinal Chemistry
Journal of medicinal chemistry
Journal of medicinal chemistry
Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat th
Autor:
Gert-Jan Wijnant, Charles E. Mowbray, Diana Caridha, Katrien Van Bocxlaer, Simon L. Croft, Richard J. Sciotti, Brian Vesely, Vanessa Yardley, Jean-Robert Ioset, Chad C. Black, Susan E. Leed, Stéphanie Braillard
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 11, Iss, Pp 129-138 (2019)
International Journal for Parasitology: Drugs and Drug Resistance
International Journal for Parasitology: Drugs and Drug Resistance
Objectives Drugs for Neglected Diseases initiative (DNDi) has identified three chemical lead series, the nitroimidazoles, benzoxaboroles and aminopyrazoles, as innovative treatments for visceral leishmaniasis. The leads discovered using phenotypic sc
Autor:
Stéphanie Braillard, Delphine Launay, Nageswararao Pulakundam, Vikram Ramanathan, Bhavesh D. Patel, Rakshit Ameta, Jignesh P Patel, Ritika Uppal
Publikováno v:
Bioanalysis. 11:1419-1435
Aim: To develop a bioanalytical method to support pharmacokinetic evaluation of DNDI-VL-2098 in mouse, rat, dog and hamster following oral administration. Results & methodology: A robust LC–MS/MS bioanalytical method was developed to quantify DNDI-
Autor:
Andrew M. Thompson, Vanessa Yardley, Christopher B. Cooper, Stéphanie Braillard, Patrick D. O'Connor, William A. Denny, Louis Maes, Eric Chatelain, Zhenkun Ma, Delphine Launay, Scott G. Franzblau, Baojie Wan
Publikováno v:
ACS medicinal chemistry letters
ACS Med Chem Lett
ACS Med Chem Lett
[Image: see text] Antitubercular 7-substituted 2-nitroimidazo[2,1-b][1,3]oxazines were previously shown to exhibit potent antileishmanial and antitrypanosomal activities, culminating in a new clinical investigational drug for visceral leishmaniasis (
Autor:
William A. Denny, Zhenkun Ma, Eric Chatelain, Scott G. Franzblau, Andrew J. Marshall, Stéphanie Braillard, Andrew M. Thompson, Delphine Launay, Christopher B. Cooper, Patrick D. O'Connor, Louis Maes, Vanessa Yardley, Baojie Wan, Suman Gupta
Publikováno v:
European journal of medicinal chemistry
Previous investigation of the potent antileishmanial properties of antitubercular 7-substituted 2-nitroimidazo[2,1-b][1,3]oxazines with biaryl side chains led to our development of a new clinical candidate for visceral leishmaniasis (DNDI-0690). With
Autor:
Stéphanie Braillard, Charles E. Mowbray, Guy Caljon, Sarah Hendrickx, Marc Ouellette, Dorien Mabille, M. Van den Kerkhof, Louis Maes, Philippe Leprohon
Publikováno v:
Antimicrobial agents and chemotherapy
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Current antileishmanial treatment is hampered by limitations, such as drug toxicity and the risk of treatment failure, which may be related to parasitic drug resistance. Given the urgent need for novel drugs, the Drugs for Neglected Diseases initiati
Autor:
Lindsay B. Tulloch, Stéphanie Braillard, Magali Van den Kerkhof, Dorien Mabille, Philippe Leprohon, Marc Ouellette, Louis Maes, Susan Wyllie, Eric Chatelain, Charles E. Mowbray, Guy Caljon, Sarah Hendrickx, Richard J. Wall
Publikováno v:
Microorganisms
Volume 9
Issue 7
Microorganisms, Vol 9, Iss 1408, p 1408 (2021)
Volume 9
Issue 7
Microorganisms, Vol 9, Iss 1408, p 1408 (2021)
Current treatment options for visceral leishmaniasis have several drawbacks, and clinicians are confronted with an increasing number of treatment failures. To overcome this, the Drugs for Neglected Diseases initiative (DNDi) has invested in the devel